AlzChem CEO Niedermaier reviews H1 2026 performance in Boersenradio interviewPUBT·Jul 31 at 02:43 AMACT
ACT: Strong H1 2026 growth driven by Specialty Chemicals, with guidance confirmed and expansions on trackQuartr·Jul 30 at 04:48 AMACT
AlzChem: Buy Rating Reiterated as Solid Operations and Capacity Expansions Support FY26 Outlook; Price Target Maintained at $200Tip Ranks·Jul 30 at 01:35 AMACT
ACT: Specialty Chemicals drove double-digit profit growth in H1 2026, with robust outlook confirmedQuartr·Jul 30 at 12:05 AMACT
AlzChem H1 FY26 EBITDA climbs 14% to EUR 64.5 million; revenue rises 6% to EUR 303.9 millionPUBT·Jul 29 at 11:55 PMACT
Pacolet Milliken unit Bushy Park selected for Alzchem U.S. production facility sitePUBT·Jul 8 at 11:12 AMACT
